News | December 15, 2021
Pfizer’s Covid-19 drug 90 % effective
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
It is a novel oral NLRP3 inflammasome inhibitor
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Subscribe To Our Newsletter & Stay Updated
